echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Johnson and Johnson and AbbVie's Imbruvica receive FDA approval for treatment of rare blood tumorly lymphocyte lymphoma

    Johnson and Johnson and AbbVie's Imbruvica receive FDA approval for treatment of rare blood tumorly lymphocyte lymphoma

    • Last Update: 2020-06-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently, Johnson and Johnson(and AbbVie's Imbruvica) were awarded the U.SFoodMedicines(Supervisory Authority) for treatment of rare blood tumorly lymphocytic lymphomaimbruvicaImbruvica (Ilutini) is an efficient, highly selective small molecule BTK inhibitor, which is mainly combined in the BTK active site cys-481, inhibits tyr-223 itself phosphorylation, so that BTK can not be completely activated, affecting the normal function of its functionImbruvica was approved by China's C
    FDA(approved for the market in August 2017 for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have received at least one treatment in the past, as well as patients with set cell lymphoma who have received at least one treatment in the past)studies have shown that errutinib has the effect of inhibiting the proliferation of malignant B cells and survival in the body, as well as in vitro cell migration and adhesion of substratesthe studythe approval was based on theDrug, which was presented earlier this month at the annual meeting of the American Society of Clinical OncologyThe experimental(the results show that Imbruvica and Rituxan can be used in conjunction with Rituxan to better alleviate the disease than using Rituxan alone.) Combined medication reduced a patient's risk of disease progression or death by 80 percent, and 82 percent of patients in the combined drug group showed no signs of cancer worsening during the 30-month treatment period, compared with 28 percent in the Rituxan alone the approval of the combined ambruvica and Rituxan drug will effectively reduce the need for chemotherapy, a common treatment option for the disease, accompanied by strong side effects
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.